Evidence map›Paper›PMID 9125574›Full record

ArticleInfection and immunity1997

Nitric oxide is required for effective innate immunity against Klebsiella pneumoniae.

W C Tsai, R M Strieter, D A Zisman, J M Wilkowski, K A Bucknell, G H Chen, T J Standiford

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 146 citations in OpenAlex.

  1. Article
  2. Effective macrophage clearance ofbioRxiv : the preprint server for biology · 2026
    Article
  3. Nitric Oxide Inhibition of Glycyl Radical Enzymes and Their Activases.Journal of the American Chemical Society · 2025
    Article
  4. Inducible antibacterial responses in macrophages.Nature reviews. Immunology · 2025
    Review
  5. Review
  6. Review
  7. Nitric Oxide Production and Effects in Group BPathogens (Basel, Switzerland) · 2022
    Article
  8. Host Immune Response to Clinical HypervirulentJournal of immunology research · 2022
    Article
  9. Structure and reactivity of chlorite dismutase nitrosyls.Journal of inorganic biochemistry · 2020
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Increased susceptibility to Klebsiella pneumonia and mortality in GSNOR-deficient mice.Biochemical and biophysical research communications · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

W C TsaiDepartment of Medicine, University of Michigan Medical School, Ann Arbor 48109-0360, USA.
R M Strieter
D A Zisman
J M Wilkowski
K A Bucknell
G H Chen
T J Standiford
University of Michigan · US

Funding

SCOR-OCCUPATIONAL AND IMMUNOLOGICAL LUNG DISEASESP50HL046487 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 1992 to 1996
–
TNF AND ICAM-1 AND LUNG ALLOGRAFT REJECTIONR01HL050057 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI STRIETER, ROBERT M · 1993 to 1997
–
NHLBI NIH HHS 1P50HL46487NHLBI NIH HHS HL35279NHLBI NIH HHS HL50057
6 · The paper itself

Abstract

Nitric oxide (NO) has been associated with protection against various parasitic and viral infections and may play a similar role in bacterial infections. We studied the role of NO in host defense against Klebsiella pneumoniae infection in the lung. Initial studies demonstrated a time-dependent increase in NO production of the lungs of CBA/J mice following the intratracheal administration of K. pneumoniae (7 x 10(2) CFU). To assess the role of NO in Klebsiella pneumonia, mice were treated intraperitoneally with either L-NAME (N-omega-nitro-L-arginine methylester), a competitive inhibitor of NO synthesis, or D-NAME, an inert enantiomer. The treatment of Klebsiella-infected mice with L-NAME resulted in a 10- and 46-fold increase in K. pneumoniae CFU in lungs and blood, respectively, at 48 h post-K. pneumoniae inoculation compared to treatment of mice with D-NAME. In addition, a greater-than-twofold increase in mortality was evident in L-NAME-treated mice compared to the mortality in control animals. No significant difference in bronchoalveolar lavage inflammatory cell profiles was noted between L-NAME- and D-NAME-treated mice with Klebsiella pneumonia. Interestingly, increased levels of tumor necrosis factor, gamma interferon, macrophage inflammatory protein 1alpha (MIP-1alpha), and MIP-2 mRNA and protein were noted in infected mice treated with L-NAME compared to the levels in mice treated with D-NAME. Importantly, the in vitro incubation of murine alveolar macrophages with L-NAME, but not with D-NAME, resulted in a significant impairment in both the phagocytosis and killing of K. pneumoniae. In total, these results suggest that NO plays a critical role in antibacterial host defense against K. pneumoniae, in part by regulating macrophage phagocytic and microbicidal activity.

Indexed as

Immunity, InnateKlebsiella pneumoniaeAnimalsBronchoalveolar Lavage FluidCells, CulturedChemokine CCL3Chemokine CCL4Chemokine CXCL2Colony Count, MicrobialEnzyme InhibitorsEnzyme-Linked Immunosorbent AssayFemaleInterferon-gammaKlebsiella InfectionsLungMacrophage Inflammatory ProteinsChemokine CCL3Chemokine CCL4Chemokine CXCL2Enzyme InhibitorsInterferon-gammaMacrophage Inflammatory ProteinsMonokinesNG-Nitroarginine Methyl EsterNitric OxideNitritesProteinsRNA, MessengerTumor Necrosis Factor-alpha

Identifiers

PMID9125574
PMCPMC175233
OpenAlexW2112204405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.